drugset / Trial / NCT05326490

Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy

NCT05326490

Phase 3 Unknown 546 enrolled PegBio Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients with Poor Glycemic Control via Metformin Hydrochloride Monotherapy

Timeline

Start
2022-05-30
Primary completion
2024-09-24
Completion
2024-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PB-201 Unknown 100 mg Oral
Background Metformin Small molecule